In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO), with a price target of $6. The company’s shares closed yesterday at $3.23.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.8% and a 34.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $6.33.
See today’s analyst top recommended stocks >>
Based on Aptose Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.29 million. In comparison, last year the company had a GAAP net loss of $3.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product portfolio includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806.
